Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-OncoFAP
- Development stage
- Preclinical
- Lead developer
- Philochem
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-OncoFAP is a fluorine-18 labeled small molecule radiopharmaceutical designed for positron emission tomography (PET) imaging of various solid tumors. It targets fibroblast activation protein (FAP), a type II transmembrane glycoprotein that is highly overexpressed by cancer-associated fibroblasts (CAFs) in the tumor stroma of most epithelial cancers, while remaining nearly undetectable in healthy adult tissues. The ligand, OncoFAP, is an ultra-high-affinity organic molecule with a dissociation constant (Kd) of approximately 680 pM. The 18F-labeled version is typically synthesized using an aluminum fluoride ([18F]AlF) complexing strategy with a NOTA chelator, allowing for efficient production and high radiochemical yields. Developed through a partnership between Philochem and Bracco (via Blue Earth Diagnostics), 18F-OncoFAP serves as a pan-cancer diagnostic tool to visualize the tumor microenvironment and potentially guide FAP-targeted therapies.
- Other names
- F-18 OncoFAPF18 OncoFAPF 18 OncoFAPOncoFAP
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 18F-OncoFAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-OncoFAP.